The forecast for cardiovascular system medicine sales in the UK shows a declining trend from 2024 to 2028, with per capita sales decreasing from $22.82 to $20.95. In 2023, these sales were likely slightly higher, given the downward trend projected through to 2028. The year-on-year percentage variation reflects a steady decline, indicating waning demand or increased market saturation. The compound annual growth rate (CAGR) over this five-year forecast period highlights a consistent decrease in per capita sales of cardiovascular medicines.
Future trends to watch for include:
- Innovations in cardiovascular healthcare and novel drug developments, potentially reversing the sales decline.
- Increasing preventive healthcare measures reducing the need for cardiovascular medications.
- Potential pricing and reimbursement policy changes impacting medicine affordability and access.
